Vico Therapeutics

Vico Therapeutics is a clinical-stage biotechnology company based in Leiden, Netherlands, focused on developing genetic medicines for neurological disorders. The company specializes in antisense oligonucleotide (ASO) therapies that target the underlying causes of rare genetic conditions while preserving essential protein functions. Vico's innovative approach addresses diseases such as Huntington’s disease, spinocerebellar ataxias (SCA1 and SCA3), Rett syndrome, and familial Alzheimer’s disease (FAD).

The company's lead candidate, VO659, targets CAG repeat expansions to reduce mutant protein levels, showing promising results in early clinical trials for Huntington’s disease. Vico's pipeline aims to provide RNA-based precision interventions for various neurological conditions. With a patient-centered mission, Vico is committed to advancing its research and clinical programs, supported by a recent €54 million ($60 million) in Series B financing. The team includes experts in oligonucleotide chemistry and drug development, dedicated to transforming outcomes for patients with unmet medical needs.